Annual report
2372.TEDINET S100TTPB
Period2023-04-01 → 2024-03-31
Filed2024-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 154
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥17.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥18.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥15.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.6bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥3.6bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥1.8bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.6bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.0bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.0bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.4bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥37.1bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥35.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥26.6bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥20.9bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥15.1bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥24.4bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥23.0bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥12.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥12.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.2bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥8.7bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥7.2bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.4bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.4bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.2bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥446m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.6bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥374m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥637m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.9bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥163m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥4.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥258m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥116.92 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥210.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥162.5 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥114.3 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.82 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥210.06 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥162.17 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥113.97 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥104.28 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,054.94 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,003.4 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥838.69 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥719.49 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥602.88 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 34.4% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.1% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.5% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.2% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 11.4% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 22.8% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 20.9% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.4% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 18.8% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,029 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 894 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 789 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 810 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 796 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥2.6bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥3.4bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥3.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥301m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥505m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.6bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥922m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥713m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥502m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.9bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥377m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.4bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥1.1bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥871m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥764m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥20.6bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥20.2bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥15.5bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥12.9bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥10.6bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥11.9bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥11.1bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥8.7bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥9.1bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥8.2bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥7.7bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥6.9bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| EPS (basic) | ¥31.21 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥117.34 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.69 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥72.55 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.45 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥117.25 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥92.5 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥72.34 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥64.5 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥40 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥55 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥717.73 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥753.89 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥681.33 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥636.93 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥577.1 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 42.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.2% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.0% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.6% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.2% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.4% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.1% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.9% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 12,338,365 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 12,338,365 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 12,306,665 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 12,285,965 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 12,048,865 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 68 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 68 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 89 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 82 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 83 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 117
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥236m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 5 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥67m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥25m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥41m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | −¥256m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥804m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥252m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥4.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥4.4bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥9.8bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.9bn |
| Advanced Medicalreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥17m |
| Advanced Medicalreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥24m |
| Advanced Medicalreportable segment | employees | at 2024-03-31 | 42 pure |
| Advanced Medicalreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥3.0bn |
| Advanced Medicalreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Advanced Medicalreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Advanced Medicalreportable segment | segment assets | at 2024-03-31 | ¥2.3bn |
| Advanced Medicalreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥133m |
| CROreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥63m |
| CROreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥234m |
| CROreportable segment | employees | at 2024-03-31 | 212 pure |
| CROreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥7.6bn |
| CROreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥6.4bn |
| CROreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1.2bn |
| CROreportable segment | segment assets | at 2024-03-31 | ¥5.5bn |
| CROreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥489m |
| Drug Discovery Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥601m |
| Medical Supportreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥1.9bn |
| Medical Supportreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥248m |
| Medical Supportreportable segment | employees | at 2024-03-31 | 10 pure |
| Medical Supportreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.1bn |
| Medical Supportreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Medical Supportreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1.0bn |
| Medical Supportreportable segment | segment assets | at 2024-03-31 | ¥10.7bn |
| Medical Supportreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥66m |
| SMOreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥97m |
| SMOreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥19m |
| SMOreportable segment | employees | at 2024-03-31 | 692 pure |
| SMOreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥9.4bn |
| SMOreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥8.7bn |
| SMOreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥704m |
| SMOreportable segment | segment assets | at 2024-03-31 | ¥7.2bn |
| SMOreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥3.5bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥2.1bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥526m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥22.1bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥17.7bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥4.4bn |
| —segment total | segment assets | at 2024-03-31 | ¥25.6bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥3.5bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥763m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥22.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥17.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥4.4bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥27.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥3.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-04-01 → 2023-03-31 | ¥876m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥118m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥159m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥88m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥70m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | −¥80m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥1.0bn |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥58m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥11.4bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥1.5bn |
| Advanced Medicalreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥6m |
| Advanced Medicalreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥30m |
| Advanced Medicalreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.5bn |
| Advanced Medicalreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.5bn |
| Advanced Medicalreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥73m |
| Advanced Medicalreportable segment | segment assets | at 2023-03-31 | ¥2.7bn |
| Advanced Medicalreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥35m |
| CROreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥576m |
| CROreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥207m |
| CROreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥5.6bn |
| CROreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥5.4bn |
| CROreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥192m |
| CROreportable segment | segment assets | at 2023-03-31 | ¥4.4bn |
| CROreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥57m |
| Drug Discovery Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥260m |
| Medical Supportreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Medical Supportreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥248m |
| Medical Supportreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| Medical Supportreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.2bn |
| Medical Supportreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥926m |
| Medical Supportreportable segment | segment assets | at 2023-03-31 | ¥8.9bn |
| Medical Supportreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥119m |
| SMOreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥0 |
| SMOreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥14m |
| SMOreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥10.3bn |
| SMOreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥10.2bn |
| SMOreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥146m |
| SMOreportable segment | segment assets | at 2023-03-31 | ¥6.6bn |
| SMOreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥5.2bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥2.6bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥500m |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥19.6bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥18.3bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥1.3bn |
| —segment total | segment assets | at 2023-03-31 | ¥22.6bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥5.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥619m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥19.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥18.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥23.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥5.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,620
| Item | Context | Value | Unit |
|---|---|---|---|
| Assets | Prior1YearInstant | 35129000000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E05352-000SMOReportableSegmentsMember | 14000000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E05352-000CROReportableSegmentMember | 207000000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E05352-000AdvancedMedicalReportableSegmentsMember | 30000000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E05352-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E05352-000MedicalSupportReportableSegmentsMember | 248000000 | JPY |
| Depreciation segment information | Prior1YearDuration_ReportableSegmentsMember | 500000000 | JPY |
| Depreciation segment information | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 118000000 | JPY |
| Depreciation segment information | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 619000000 | JPY |
| Depreciation segment information | Prior1YearDuration_ReconcilingItemsMember | 58000000 | JPY |
| Depreciation segment information | Prior1YearDuration | 677000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E05352-000SMOReportableSegmentsMember | 23000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E05352-000CROReportableSegmentMember | 55000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E05352-000AdvancedMedicalReportableSegmentsMember | 38000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E05352-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E05352-000MedicalSupportReportableSegmentsMember | － | JPY |
| Amortization of goodwill sga | Prior1YearDuration_ReportableSegmentsMember | 117000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 120000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Amortization of goodwill sga | Prior1YearDuration | 120000000 | JPY |
| Equity in earnings losses of affiliates | Prior1YearDuration_jpcrp030000-asr_E05352-000SMOReportableSegmentsMember | － | JPY |
| Equity in earnings losses of affiliates | Prior1YearDuration_jpcrp030000-asr_E05352-000CROReportableSegmentMember | － | JPY |
| Equity in earnings losses of affiliates | Prior1YearDuration_jpcrp030000-asr_E05352-000AdvancedMedicalReportableSegmentsMember | － | JPY |
| Equity in earnings losses of affiliates | Prior1YearDuration_jpcrp030000-asr_E05352-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Equity in earnings losses of affiliates | Prior1YearDuration_jpcrp030000-asr_E05352-000MedicalSupportReportableSegmentsMember | － | JPY |
| Equity in earnings losses of affiliates | Prior1YearDuration_ReportableSegmentsMember | － | JPY |
| Equity in earnings losses of affiliates | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Equity in earnings losses of affiliates | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Equity in earnings losses of affiliates | Prior1YearDuration_ReconcilingItemsMember | 7000000 | JPY |
| Equity in earnings losses of affiliates | Prior1YearDuration | 7000000 | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration_jpcrp030000-asr_E05352-000SMOReportableSegmentsMember | － | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration_jpcrp030000-asr_E05352-000CROReportableSegmentMember | － | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration_jpcrp030000-asr_E05352-000AdvancedMedicalReportableSegmentsMember | － | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration_jpcrp030000-asr_E05352-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration_jpcrp030000-asr_E05352-000MedicalSupportReportableSegmentsMember | － | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration_ReportableSegmentsMember | － | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration_ReconcilingItemsMember | 21000000 | JPY |
| Investments in entities accounted for using equity method | Prior1YearDuration | 21000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E05352-000SMOReportableSegmentsMember | 0 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E05352-000CROReportableSegmentMember | 576000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E05352-000AdvancedMedicalReportableSegmentsMember | 6000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E05352-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E05352-000MedicalSupportReportableSegmentsMember | 1971000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_ReportableSegmentsMember | 2554000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 876000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 3431000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_ReconcilingItemsMember | 1038000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |